Innovation Pharmaceuticals Inc (IPIX)

[HFM2]

So, we're half way through the GMU "extra" study. Will the work Dr. Narayanan does be the third peer-review article this summer for B?

As part of this project, Narayanan will first determine the EC50 values, or the concentration of the drug that gives a half-maximal response.

From there, Naryanan and her collaborators will evaluate if Brilacidin has direct virus-killing activity.

They will also assess whether Brilacidin can be provided as a second dose to infected cells without inducing toxicity.

As they work, the researchers will time their experiments to determine the appropriate timing of treatment.

Funding for this research began in May 2020 and will conclude in late August 2020

https://www.news-medical.net/news/20200605/George-Mason-researcher-examining-the-use-of-Brilacidin-for-treatment-of-coronavirus-infections.aspx